ABSTRACT There is evidence that aspirin is partially effective in the prophylaxis of various vasoocclusive disorders. This article reviews pharmacologic opportunities for improvement over and above the therapeutic effect of aspirin. It is concluded that several rational possibilities merit consideration, in particular, the use of combinations of drugs that affect the thrombotic process at different points. Such strategies will ultimately require validation by clinical trial.
VASCULAR OCCLUSIONS, especially in the arterial circulation, are the principal source of mortality and morbidity in Western society. Occasionally the cause is a generalized disease process that affects blood flow (e.g., hyperviscosity states such as macroglobulinemia or polycythemia) or blood vessel walls (e.g., giant cell arteritis or syphilitic vasculitis). Such diseases offer specific points of therapeutic attack. Recently the pathophysiology of hypercoagulable states associated with protein C deficiency, antithrombin III deficiency, and the lupus anticoagulant have been elucidated.1-' Such insights provide new therapeutic approaches to these disorders and no doubt further instances of such specific entities will be discovered in the future. However, overwhelmingly the most common pathology in the arterial circulation is the atheromatous plaque and related thrombosis.
Atheromatous plaques are very common, but they are usually clinically undetectable. Risk The recent finding of raised levels of the urinary metabolite of prostacyclin in patients with severe atheromatous disease9 suggests that a biochemical approach to detecting the extent of atheroma is not impossible, although other markers of arterial damage may prove to be more sensitive. Whether some such method would be worthwhile as a screening technique will depend on its ability to identify a subgroup at particular risk and to follow changes in response to a therapeutic measure. Some interventions (such as stopping smoking) are so clearly advantageous that there is no need to restrict them to a population at particular risk. Some dietary measures (such as avoidance of gross excesses of fats and cholesterol) probably fall into the same category, whereas others (e.g., increased consumption of food rich in eicosapentaenoic acid) are more contentious, and certainly require further study. This is also true of most drugs that might be used in the primary prevention of atheromatous disease.
This article concentrates on possibilities for drug therapy, and particularly on drugs acting on the eicosanoid cascade that may modify platelet/vessel wall interactions. The platelet is an attractive target for pharmacologic attack, first because of its role in thrombosis. The probable efficacy of aspirin in the secondary prevention of myocardial infarction'0 and of stroke and death in patients experiencing transient ischemic attacks'1 is encouraging in this context. Second, platelets are also implicated, albeit indirectly, in the development of the atheromatous plaques themselves. Thus, experimental intimal proliferative lesions in rabbits do not occur in thrombocytopenic animals.12 Pigs with von Willebrand's disease in which platelets fail to adhere to the subendothelium develop fewer atheromatous lesions than do control pigs both on normal and high-cholesterol diets.'3 It has been suggested that platelet-derived growth factor may be the stimulus to the smooth muscle cell proliferation that is central to the development of atheroma,14 although the evidence for this is limited to observations on cultured cells. Whether or not platelet-derived growth factor proves to be an important link between platelets and atheromatous plaques, antiplatelet drugs can influence atheroma formation, at least experimentally: proliferative arterial lesions caused by homocystine infusions in baboons were prevented by dipyridamole. 1 ' New therapeutic avenues may arise from the application of new drugs or from more rational use of existing ones. Antiplatelet drugs offer opportunities of both kinds. Their value in secondary prevention must be judged against existing therapies (aspirin, anticoagulants, /3-blockers), in terms of efficacy, adverse reactions, and cost. In the case of primary prevention, controlled studies will be needed, such as the study of aspirin in British doctors in progress under the direction of Sir Richard Doll. Antiplatelet drugs include the following categories: (1) cyclooxygenase inhibitors, (2) thromboxane synthase inhibitors, (3) thromboxane receptor antagonists, (4) antiaggregatory prostaglandin (PG) agonists, and (5) It is unlikely that other cyclooxygenase inhibitors will have greater efficacy than aspirin, but it is possible that some may be of value in specific circumstances such as renal impairment or gastric intolerance. In this context the selectivity of sulindac in sparing renal cyclooxygenase in vivo23 is noteworthy. This selectivity has recently been questioned. 24 However, in patients with mild renal impairment ibuprofen caused a fall in glomerular filtration, whereas sulindac, in a dose that caused substantial inhibition of platelet thromboxane synthesis, had no effect on renal function or prostaglandin production. 25 The combined lipoxygenase/cyclooxygenase inhibitor BW 755C does not inhibit gastric prostacyclin synthesis and is not ulcerogenic in rats at doses that do inhibit the formation of PGs in inflammatory exudate,26 raising the possibility of cyclooxygenase inhibitors that specifically spare the stomach.
Thromboxane synthase inhibitors. It was hoped that this class of drug, exemplified by dazoxiben, would be an improvement over cyclooxygenase inhibitors for two reasons. First, it would circumvent the "aspirin dilemma" referred to above, since vascular PGI2 synthesis would be unimpaired. Since low-dose aspirin therapy achieves selective inhibition of platelets at low cost, this rationale is not so attractive as at first appeared. A second reason these drugs could be superior to cyclooxygenase inhibitors is that by diverting endoperoxide precursor from platelets to vessel wall, they might augment prostacyclin synthesis. However, in the light of the above discussion, it is clear that they have real potential for use in combination with a thromboxane synthase inhibitor. Thus, by blocking thromboxane receptors, the proaggregatory actions of the endoperoxides will be prevented while permitting endoperoxide diversion and hence augmented local vascular prostacyclin production.
Antiaggregatory PG agonists. PGI, and PGD2 act on different receptors on the platelet to increase intracellular cyclic AMP and inhibit aggregation. There is a real prospect that a drug acting on such a receptor could improve on the efficacy of aspirin. Thus, there are stimuli to platelet aggregation, notably thrombin, that are likely to be highly relevant in the context of an evolving thrombus and are independent of platelet thromboxane synthesis. Aspirin is unlikely to be helpful when such stimuli predominate, whereas all stimuli to aggregation are inhibited by increased intracellular cyclic AMP. However, there are difficulties with the use of PGI, or PGD2 themselves because of their chemical and biological instability and because of their effects on tissues other than the platelets. These difficulties may be partly surmounted by the use of stable analogues, e.g., BW 245C, which acts on PGD, receptors37 and inhibits platelet function in man." However, to date such analogues have lacked selectivity for platelet receptors and have caused flushing and other signs of vasodilation. A major therapeutic prospect is the development of an agonist specific for platelet as opposed to vascular smooth muscle receptors, although desensitization, which occurs at PGI2 receptors,39 might limit the usefulness of such a drug.
Platelet phosphodiesterase inhibitors. These drugs (e.g., dipyridamole) also increase platelet cyclic AMP, but by inhibiting its degradation rather than stimulating its synthesis. Dipyridamole has generally been disappointing when used in conjunction with conventional (high) dose aspirin, perhaps because in this circumstance antiaggregatory PGs are inhibited, so their stimulus to platelet cyclic AMP synthesis is reduced. In some studies dipyridamole has been reported to potentiate PG!,,40 although this has not been observed during short (15 to 45 min) infusions of PGI, in healthy volunteers.4' It is therfore logical to consider the use of a platelet phosphodiesterase inhibitor in conjunction with a platelet-selective long-acting antiaggregatory PG agonist, should such a drug become available (cf the combined use of /32-agonist and theophylline in asthma). This also offers a potential means of circumventing the problem of desensitization alluded to above by enabling the agonist to be given at greater intervals without reducing its effect on cyclic AMP.
Conclusion. Existing antiplatelet drugs and ones that will likely soon be available offer real possibilities for secondary and perhaps even for primary prevention of vasoocclusive disease. Several logical combinations suggest themselves. In addition to those discussed, there is also the possibility of combining drugs effective on other components of the thrombotic process (e.g., anticoagulants) with a platelet selective PG agonist. This possibility is particularly attractive, both because of the evidence that levels of coagulation factors are predictors of risk of cardiovascular mortality,'
and because of the evidence that anticoagulants are effective in the secondary prevention of myocardial infarction.42 Furthermore, the coagulation system and platelet function are interdependent in several ways. Thus, for instance, thrombin stimulates platelet aggregation and platelet-derived phospholipid accelerates several stages of the coagulation cascade. There is thus the possibility of synergy between anticoagulant and antiplatelet drugs. The beneficial effect of /3-blockers may well be additive with antiplatelet therapy. It is possible that in the future such combinations will be as common as combination therapy is today in the treatment of hypertension. However, for such an approach to be applied with precision, an intermediate end point that is a continuous variable (rather than quantal end points of stroke, myocardial infarction, etc.) must be devised. It is conceivable that prostacyclin and thromboxane metabolites or some other biochemical reflection of atheroma and platelet activation may provide this. If so, the time may soon be ripe for the validation of such strategies by clinical trial. The falling incidence of stroke and myocardial infarction in several populations makes the use of concurrent controls essential in such trials. The magnitude of effect that can reasonably be hoped for will entail large numbers of subjects studied for several years10 so such trials will inevitably be very costly. It is therefore crucial that the right questions are asked.43
